Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Anti-PD-1 Timing in Chest Tumors
NCT05044728Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital. Primary endpoints: Functional subsets of peripheral CD8 positive T cells at 1 year, Overall response rate at 1 year and 2 more. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05044728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044728.